Report
Damien Conover
EUR 100.00 For Business Accounts Only

Merck and Bristol Post Strong Data, Reaffirming Immuno Oncology’s Potential and Merck’s Leadership

At the annual meeting of the American Association for Cancer Research (AACR), clinical data is emerging that is reinforcing Merck’s leading position in the largest immuno-oncology area of first-line non-small cell lung cancer (NSCLC), but we don’t expect any major changes to our fair value estimates based on the data and continue to view key immuno-oncology players Merck, Bristol, and Roche as undervalued. Additionally, the impressive clinical data at AACR from both Bristol and Merck in the unme...
Underlying
Merck & Co. Inc.

Merck & Co. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company's segments are: Pharmaceutical, which includes human health pharmaceutical products that consist of therapeutic and preventive agents for the treatment of human disorders, and human health vaccine products that consist of preventive pediatric, adolescent and adult vaccines; and Animal Health, which discovers, develops, manufactures and markets veterinary pharmaceuticals, vaccines and health management solutions and services, as well as a suite of digitally connected identification, traceability and monitoring products.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Damien Conover

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch